Overview

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

Status:
Active, not recruiting

Trial end date:
2023-01-01

Target enrollment:

Participant gender:

Summary

This is a study to evaluate the long-term safety and tolerability of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis (PSO).

Phase:

Phase 3

Details

Lead Sponsor:

UCB Biopharma S.P.R.L.
UCB Biopharma SRL